Acne Vulgaris Clinical Trial
Official title:
The Effects of a Botanical Skin Care Regimen on Mild to Moderate Acne and the Microbiome
The purpose of this study is to analyze changes in acne and changes in the gut and skin microbiome with the use of a multi-step botanical skin care regimen in those with mild to moderate acne.
Status | Not yet recruiting |
Enrollment | 20 |
Est. completion date | March 1, 2023 |
Est. primary completion date | July 1, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 15 Years to 45 Years |
Eligibility | Inclusion Criteria: - Subjects 15 years of age until 45 years of age. - The presence of mild to moderate acne based on investigator global assessment. Exclusion Criteria: - The presence of severe acne as noted by the investigator global assessment. - Those with a nut allergy. - Those who are unwilling to discontinue oral probiotic-based supplementation to meet the washout criteria prior to enrolling. - Those who are unwilling to discontinue topical antibiotics and topical benzoyl peroxide to meet the washout criteria prior to enrolling. - Individuals who are unwilling to discontinue vitamin E containing supplements during the washout and intervention. - Individuals who have been on an oral antibiotic for acne within the previous 1 month. - Individuals who are pregnant or breastfeeding. - Individuals who have changed any of their hormonal based contraception within 3 months prior to joining the study. - Oral supplementation that has nuts in it. - Use of isotretinoin within the three months prior to joining the study. - Current tobacco smoker or a tobacco smoking history of greater than 10 pack-years. |
Country | Name | City | State |
---|---|---|---|
United States | Integrative Skin Science and Research | Sacramento | California |
Lead Sponsor | Collaborator |
---|---|
Integrative Skin Science and Research | Codex Beauty Corporation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Total lesion count | Number of of inflammatory lesions, and open and closed comedones | 8 weeks | |
Secondary | Inflammatory lesion count | Number of inflammatory lesions | 4 weeks | |
Secondary | Inflammatory lesion count | Number of inflammatory lesions | 8 weeks | |
Secondary | Non-inflammatory lesion count | Number of open and closed comedones | 4 weeks | |
Secondary | Non-inflammatory lesion count | Number of open and closed comedones | 8 weeks | |
Secondary | Investigator global assessment (IGA) of acne | Validated scale for global assessment of acne. Scale is 0 to 4 with 4 indicating greater severity of acne | 4 weeks | |
Secondary | Investigator global assessment (IGA) of acne | Validated scale for global assessment of acne. Scale is 0 to 4 with 4 indicating greater severity of acne | 8 weeks | |
Secondary | Sebum excretion | Measure of skin sebum via sebumeter | 4 weeks | |
Secondary | Sebum excretion | Measure of skin sebum via sebumeter | 8 weeks | |
Secondary | Gut microbiome assessment | Gut microbiome shift for short-chain fatty acid producing bacteria via stool sample | 4 weeks | |
Secondary | Gut microbiome assessment | Gut microbiome shift for short-chain fatty acid producing bacteria via stool sample | 8 weeks | |
Secondary | Skin microbiome diversity | Shift in Shannon diversity of the skin microbiome | 4 weeks | |
Secondary | Skin microbiome diversity | Shift in Shannon diversity of the skin microbiome | 8 weeks | |
Secondary | Positive and Negative Affect Schedule (PANAS-SF) | Survey assessing positive and negative mood states. Scores range from 10 to 50 with higher scores representing positive affect | 4 weeks | |
Secondary | Positive and Negative Affect Schedule (PANAS-SF) | Survey assessing positive and negative mood states. Scores range from 10 to 50 with higher scores representing positive affect | 8 weeks | |
Secondary | Diurnal Cortisol Slope | 4 salivary cortisol collections to assess diurnal slope | 4 weeks | |
Secondary | Diurnal Cortisol Slope | 4 salivary cortisol collections to assess diurnal slope | 8 weeks | |
Secondary | Salivary Sex Hormone Levels | 1 salivary collection to assess estradiol, progesterone, testosterone, DHEAS | 4 weeks | |
Secondary | Salivary Sex Hormone Levels | 1 salivary collection to assess estradiol, progesterone, testosterone, DHEAS | 8 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04321070 -
Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris
|
Phase 1 | |
Recruiting |
NCT05755256 -
The Impact of Probiotics on Skin Hydration in Youth With Mild Acne
|
Phase 2 | |
Completed |
NCT05131373 -
Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01445301 -
Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects
|
Phase 3 | |
Completed |
NCT03303170 -
Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris
|
N/A | |
Completed |
NCT04698239 -
Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.
|
N/A | |
Completed |
NCT02886715 -
A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris
|
Phase 3 | |
Terminated |
NCT02924428 -
Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris
|
N/A | |
Completed |
NCT02709902 -
Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris
|
Phase 1 | |
Not yet recruiting |
NCT02491060 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Not yet recruiting |
NCT02535871 -
A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris
|
Phase 3 | |
Not yet recruiting |
NCT02525822 -
Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris
|
Phase 2 | |
Completed |
NCT02250430 -
A Phase 1 Study Assessing Local Cutaneous Effects of SB204
|
Phase 1 | |
Completed |
NCT02913001 -
The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne
|
N/A | |
Completed |
NCT01694810 -
Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT01769664 -
A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris
|
Phase 1 | |
Completed |
NCT01727440 -
Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment
|
N/A | |
Completed |
NCT01194375 -
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris
|
Phase 2 | |
Completed |
NCT02524665 -
8 Week Study to Evaluate and Compare the Efficacy and Tolerability of MAXCLARITY II and MURAD To Treat Acne
|
Phase 4 | |
Completed |
NCT01706250 -
U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™
|
Phase 4 |